Drug Trial Radar · NCT06623110
Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease
Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Jan 1, 2025
Primary completion
Jan 1, 2027
Study completion Jan 1, 2029
Sponsor
- Lead sponsor
- Glenn J. HannaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Replimune, Inc.
- First posted
- Oct 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to understand the safety, tolerability, and potential efficacy of an injected immune therapy called RP2 to treat oral precancer conditions and prevent progression to an oral cancer. The name of the study drug involved in this study is: -RP2 (a genetically modified live Herpes Simplex V-1 strain)
Conditions
- High-Risk Oral Precancerous Disease
Interventions
RP2 InjectionBiological
Genetically modified live HSV-1 virus, 3.0 mL single-use glass vials, via intralesional (into a lesion) injection per protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Best Overall ResponseTime frame: Up to 1 year
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.